Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 2NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 100Other hematologic neoplasm 43Plasma cell 6Sarcoma 4Myeloid 4Dermatologic 2Classical hematology 2Thoracic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 80Paclitaxel 52Trastuzumab 41Tamoxifen 40Doxorubicin 39Specimen Handling 35Docetaxel 35Magnetic Resonance Spectroscopy 34Radiotherapy 33Taxes 30Fluorouracil 26Chemotherapy, Adjuvant 26Carboplatin 24Epirubicin 22Biopsy 22Filgrastim 21Neoadjuvant Therapy 19Methotrexate 19aldesleukin 17Peripheral Blood Stem Cell Transplantation 16Bevacizumab 14Anastrozole 14exemestane 13Lapatinib 13veliparib 12CMF regimen 12sargramostim 11Goserelin 11Fulvestrant 11Capecitabine 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Rituximab × Breast × Clear all
NCT00001805 2008-03-04

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
20 enrolled
BreastGastrointestinalThoracic

Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡